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Serine racemase (SR) is a pyridoxal 50-phosphate (PLP)-containing enzyme that
converts l-serine to d-serine, an endogenous co-agonist for the N-methyl-d-
aspartate receptor (NMDAR) subtype of glutamate ion channels. SR regulates
d-serine levels by the reversible racemization of l-serine to d-serine, as well as
the catabolism of serine by ,-elimination to produce pyruvate. The modulation
of SR activity is therefore an attractive therapeutic approach to disorders
associated with abnormal glutamatergic signalling since it allows an indirect
modulation of NMDAR function. In the present study, a 1.89 A˚ resolution
crystal structure of the human SR holoenzyme (including the PLP cofactor) with
four subunits in the asymmetric unit is described. Comparison of this new
structure with the crystal structure of human SR with malonate (PDB entry
3l6b) shows an interdomain cleft that is open in the holo structure but which
disappears when the inhibitor malonate binds and is enclosed. This is owing to a
shift of the small domain (residues 78–155) in human SR similar to that
previously described for the rat enzyme. This domain movement is accompanied
by changes within the twist of the central four-stranded -sheet of the small
domain, including changes in the ’– angles of all three residues in the
C-terminal -strand (residues 149–151). In the malonate-bound structure, Ser84
(a catalytic residue) points its side chain at the malonate and is preceded by a
six-residue -strand (residues 78–83), but in the holoenzyme the -strand is only
four residues (78–81) and His82 has ’– values in the -helical region of the
Ramachandran plot. These data therefore represent a crystallographic platform
that enables the structure-guided design of small-molecule modulators for this
important but to date undrugged target.
1. Introduction
N-Methyl-d-aspartate receptors (NMDARs) are a subtype of
ionotropic glutamate receptors that are highly expressed in
the central nervous system (CNS) and are involved in the
excitatory synaptic transmission and synaptic plasticity that
form the basis of many critical CNS functions (Traynelis et al.,
2010). Glutamatergic and more speciﬁcally NMDAR
dysfunction has been implicated in various CNS disorders,
including Alzheimer’s disease (Za´dori et al., 2014; Balu et al.,
2019), amyotrophic lateral sclerosis (ALS; Paul & de Beller-
oche, 2014), neuropathic pain (Petrenko et al., 2003), schizo-
phrenia (Howes et al., 2015) and major depressive disorder
(Niciu et al., 2014). Most nonselective, direct NMDAR
antagonists (such as ketamine) that have shown efﬁcacy at
relieving symptoms of neuropathic pain (Zhou et al., 2011) and
treatment-resistant depression (TRD; Daly et al., 2019;
Vasilescu et al., 2017) have undesirable side effects that restrict
their clinical utility (Pomarol-Clotet et al., 2006; Niesters et al.,
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2014; Schatzberg, 2019). Hence, indirect or subtype-speciﬁc
modulators of NMDAR function offer the potential to have
reduced side effects relative to nonselective antagonists. One
approach is to target the NMDAR co-agonist d-serine, which
is required for the activation of NMDARs via binding to the
glycine modulatory site, so-called because glycine is an alter-
native endogenous co-agonist (Kleckner & Dingledine, 1988).
The neuroanatomical distribution suggests that d-serine is
primarily localized to the forebrain, with a distribution that
mirrors that of the GluN2A- and GluN2B-containing subtypes
of NMDAR, while glycine is predominantly located in the
hindbrain and brainstem, indicating a potentially selective
avenue for modulating glutamate neurotransmission in the
CNS (Papouin et al., 2012). The critical role of d-serine has
been described in neuropsychiatric conditions including
schizophrenia (Tsai et al., 1998; Hashimoto et al., 2003; Labrie
et al., 2012), depression (Malkesman et al., 2012; Otte et al.,
2013) and Alzheimer’s disease (Hashimoto et al., 2004; Wu et
al., 2004; Madeira et al., 2015). The recent approval of esket-
amine, an enantiomer of racemic ketamine, as a nasal spray for
treatment-resistant depression (Daly et al., 2019; Schatzberg,
2019; Swainson et al., 2019; Fedgchin et al., 2019) demonstrates
the therapeutic value of targeting NMDARs.
Serine racemase (SR) is a pyridoxal 50-phosphate (PLP)-
containing enzyme that converts l-serine to d-serine
(Wolosker et al., 1999); therefore, inhibitors of SR that reduce
the production of d-serine are hypothesized to have thera-
peutic beneﬁts in disorders associated with NMDAR hyper-
function (Coyle & Balu, 2018). Almost all endogenous
d-serine is produced by SR, as demonstrated by the obser-
vation that SR-knockout mice have an 80–90% reduction in
d-serine levels (Balu et al., 2013). Several groups have tried to
identify new SR inhibitors that are potent, selective and
structurally distinct from the many well described amino-acid
analogues, but overall there has been relatively little progress
(Jira´skova´-Vanı´cˇkova´ et al., 2011; Beato et al., 2015; Vorlova´ et
al., 2015; Watanabe et al., 2016; Mori et al., 2017). One of the
more promising approaches identiﬁed a series of dipeptide-
like inhibitors with a clear structural motif and slow-binding
kinetics (Dixon et al., 2006), which later provided the query
molecule for an in silico screen (Mori et al., 2014). The
resulting amide inhibitors and halogen-substituted derivatives
showed improved inhibitory activity (compared with classical
SR inhibitors), binding afﬁnity and ligand efﬁciency, but
limited potency, with reported IC50 values of 0.28, 0.27 and
0.14 mM for the best compounds (Mori et al., 2017). Overall,
there are a negligible number of drug-like SR inhibitors and
none that have been conﬁrmed by crystallography.
X-ray crystal structures of mammalian SR were ﬁrst
published for the rat holoenzyme (1.8 A˚ resolution) and the
rat and human malonate (an orthosteric inhibitor)-bound
complexes (1.9 and 1.5 A˚ resolution), and more recently for
the wild-type human holoenzyme (1.8 A˚ resolution) (Taka-
hara et al., 2018; Smith et al., 2010). SR is organized as a dimer,
with each monomer comprised of a large domain containing
the essential PLP cofactor covalently bound to Lys56 and a
small domain that undergoes a ligand-induced reorientation
upon binding at the domain interface (Smith et al., 2010). The
organization of the domain boundaries is described as follows
for the human SR–malonate complex (PDB entry 3l6b; Smith
et al., 2010): the small domain (residues 55–151) contains a
central four-stranded -sheet (residues 149–151, 78–83, 101–
108 and 124–128) and four -helices (residues 55–66, 85–98,
111–121 and 131–147), and the large domain (residues 1–68
and 157–340) contains a seven-stranded twisted -sheet
surrounded by ten -helices.
PLP-dependent enzymes can be categorized as fold types I–
IV, according to the similarity of their secondary structure
(Jansonius, 1998). SR belongs to the fold type II family, along
with its closest homologue serine dehydratase (SDH). SDH is a
mammalian enzyme that catalyses the dehydration of l-serine
to pyruvate and ammonia, and shares 23% sequence identity
with SR. Proteins in this group have two domains and each
contains a -sheet core surrounded by -helices. Accordingly,
the small domain of SDH consists of a central four-stranded
-sheet surrounded by four -helices (Yamada et al., 2003; Sun
et al., 2005), and corresponds to residues 55–151 of SR. In the
original crystal structure paper, Smith and coworkers deﬁned
the small domain as residues 78–155, and did not include helix
3 (55–66) in the small domain because it precedes a mobile
hinge region (residues 69–77) and is not involved in the
rearrangement of the small domain (Smith et al., 2010).
Further, their deﬁnition of a ﬂexible loop region connecting
both domains comprised of residues 68–77 and 145–149
(Smith et al., 2010) is somewhat problematic as residues 145–
149 are deﬁned as being within the small domain and are
before the ﬁnal -strand of the central -sheet.
In the present study, we have determined the structure of
the holo form of human SR and used this in structural
comparisons with the previously published human malonate-
bound complex. We have used the more soluble Cys2Asp,
Cys6Asp mutant (Smith et al., 2010; Section 2) as this
construct improves the solubility during the puriﬁcation
process, while producing no signiﬁcant structural changes at
the N-terminus when compared with wild-type protein (PDB
entry 5x2l; Takahara et al., 2018). Moreover, we have sought to
clarify the ambiguity regarding the domain-boundary deﬁni-
tions of SR, particularly in the context of ligand-induced small
domain rearrangement. A more developed understanding of
the conformational changes that occur upon malonate binding
may further inform and enable strategies, such as structure-
guided drug design, for the development of novel inhibitors of
SR with more drug-like properties.
2. Materials and methods
2.1. Macromolecule production
The pET-24a vector containing a C-terminal polyhistidine
(His6) tag and two cysteine-to-aspartate point mutations
(Cys2Asp, Cys6Asp) to improve solubility during the puriﬁ-
cation process (Smith et al., 2010) and improve the overall
yield (unpublished observations) was chemically transformed
into Escherichia coli BL21 CodonPlus(DE3)-RIL cells, and
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plated onto LB agar plates (50 mg ml1 kanamycin and
35 mg ml1 chloramphenicol) for overnight incubation at
37C. Pre-cultures grown overnight in LB from a single colony
at 37C were used to inoculate 8  1 l LB medium supple-
mented with 50 mg ml1 kanamycin, 34 mg ml1 chloram-
phenicol and 0.01% pyridoxine (the enzyme contains PLP as a
cofactor). The cells were grown at 37C to an optical density at
600 nm (OD600) of 0.6, at which point gene expression was
induced with 0.5 mM isopropyl -d-1-thiogalactopyranoside
(IPTG) and cell growth was continued for a further 16–18 h at
25C. The cells were harvested by centrifugation at 6500g for
20 min at 4C and stored at 80C.
The cell pellet was solubilized and lysed by sonication while
on ice and the lysate was then clariﬁed at 25 000g for 60 min at
4C. The supernatant was loaded onto a TALON column for
initial puriﬁcation by immobilized-metal afﬁnity chromato-
graphy via interaction of the SR His tag with the nickel-
containing beads of the TALON resin. The protein-containing
fractions (as determined by SDS–PAGE) were loaded onto a
Superdex 200 (26/60) column equilibrated with buffer
consisting of 20 mM Tris pH 8.0, 100 mM NaCl, 5 mM DTT,
50 mM PLP, 1 mM MgCl2, 10% glycerol. The SR-containing
fractions (as determined by SDS–PAGE) were pooled and
concentrated to 15 mg ml1 before being ﬂash-frozen in liquid
nitrogen and stored at 80C. The protein concentration was
determined by UV spectrophotometry at 280 nm using a
molar extinction coefﬁcient of 29 910 M1 cm1 and a mole-
cular weight of 37.4 kDa. The protein yield was approximately
3 mg per litre of culture and the puriﬁed protein had a purity
of >95%. Macromolecule-production information is summar-
ized in Table 1.
2.2. Crystallization
Human holo SR was crystallized by the sitting-drop vapour-
diffusion method. A reservoir solution consisting of 15% PEG
3350, 100 mM bis-Tris pH 6.5, 250 mM MgCl2 was mixed with
the protein solution (6.5 mg ml1 SR and 5 mM DTT) in a 1:1
ratio and equilibrated at 20C. Crystals appeared within 48 h
and grew to full size (50 mm) within seven days. The crystal
used for the diffraction experiment was cryoprotected by
sequential soaking in reservoir solution supplemented with
10%, 20% and 30% glycerol prior to data collection. Crys-
tallization information is summarized in Table 2.
2.3. Data collection and processing
An X-ray data set was collected from a single cryocooled
crystal on beamline I03 at the Diamond Light Source
synchrotron (Table 3).
2.4. Structure solution and refinement
The structure was solved by molecular replacement using
the crystal structure of the rat SR holoenzyme (Smith et al.,
2010; the rat holoenzyme was used because structure solution
occurred prior to the deposition of PDB entry 5x2l) and was
reﬁned with REFMAC5 (Murshudov et al., 2011) and
phenix.reﬁne (Adams et al., 2010) with iterative cycles of
model building in Coot (Emsley et al., 2010). The ﬁnal struc-
ture had reasonable geometry and R factors (Table 4) and the
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Table 1
Macromolecule-production information.
DNA source pET-24a vector containing the human SR
gene with two point mutations
(Cys2Asp, Cys6Asp) and a C-terminal
His6 tag kindly donated by Evotec for
the purposes of this research
Cloning vector pUC57
Expression vector pET-24a
Expression host E. coli BL21 CodonPlus(DE3)-RIL
Complete amino-acid sequence
of the construct produced
MDAQYDISFADVEKAHINIRDSIHLTPVLT
SSILNQLTGRNLFFKCELFQKTGSFKIR
GALNAVRSLVPDALERKPKAVVTHSSGN
HGQALTYAAKLEGIPAYIVVPQTAPDCK
KLAIQAYGASIVYCEPSDESRENVAKRV
TEETEGIMVHPNQEPAVIAGQGTIALEV
LNQVPLVDALVVPVGGGGMLAGIAITVK
ALKPSVKVYAAEPSNADDCYQSKLKGKL
MPNLYPPETIADGVKSSIGLNTWPIIRD
LVDDIFTVTEDEIKCATQLVWERMKLLI
EPTAGVGVAAVLSQHFQTVSPEVKNICI
VLSGGNVDLTSSITWVKQAERPASYQSV
SVHHHHHH
Table 2
Crystallization.
Method Sitting-drop vapour diffusion
Plate type MRC Maxi 48-well
Temperature (K) 293
Protein concentration (mg ml1) 6.5
Buffer composition of protein
solution
20 mM Tris–HCl pH 8.0, 100 mM NaCl,
10% glycerol, 1 mM MgCl2, 0.5 mM
ATP, 50 mM PLP, 5 mM DTT
Composition of reservoir solution 100 mM bis-Tris pH 6.5, 15% PEG 3350,
250 mM MgCl2
Volume and ratio of drop 2 ml, 1:1
Volume of reservoir (ml) 100
Table 3
Data collection and processing.
Values in parentheses are for the outer shell.
Diffraction source I03, Diamond Light Source
Wavelength (A˚) 0.97625
Temperature (K) 100
Detector PILATUS3 6M, Dectris
Crystal-to-detector distance (mm) 342.34
Rotation range per image () 0.1
Total rotation range () 180
Exposure time per image (s) 0.1
Space group P21
a, b, c (A˚) 48.20, 155.74, 85.58
, ,  () 90, 98.48, 90
Mosaicity () 0.184
Resolution range (A˚) 42.73–1.89 (1.92–1.89)
Total No. of reﬂections 331938 (16869)
No. of unique reﬂections 98693 (4996)
Completeness (%) 99.2 (99.7)
Multiplicity 3.4 (3.4)
hI/(I)i 10.5 (1.5)
Rmerge 0.061 (0.947)
Rr.i.m. 0.071 (1.086)
CC1/2 0.997 (0.543)
Overall B factor from Wilson plot (A˚2) 36.3
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four subunits in the asymmetric unit contained residues A4–
A325, B4–B326, C3–C325 and D4–D325.
Towards the end of the reﬁnement, difference maps clearly
showed electron density for a second position for the
-strands in the central -sheet of the small domain in the C
subunit (the small domain of human SR is deﬁned as residues
78–155). The small domain from the C subunit (residues C74–
C152) was rigid-body ﬁtted into the difference map in Coot,
and the new position (and the original position) were reﬁned
with occupancies in steps of 0.1 (0.1/0.9, 0.2/0.8 etc.). Lower R
factors (and Rfree) suggested that the occupancy of the alter-
nate ‘new’ position was approximately 0.3 (and that of the
original position was 0.7). There is some variability in the
position of the small domain relative to the large domain when
all four subunits are compared (Supplementary Fig. S1).
Across the four chains in the asymmetric unit (A, B, C and
D), the overall ordering of the residues was reasonable, with
exceptions at the N-terminus (residues 1–3) and C-terminus
(residues 326–340). The small domains (residues 78–151)
appear to be more mobile, with higher temperature factors
(57.1, 100.4, 76.9 and 66.4 A˚2 for the small domains from
chains A, B, C and D, respectively, compared with 34.9, 58.4,
53.7 and 38.6 A˚2 for the corresponding large domains). The
ﬂexible loop region (residues 66–77) is complete and well
deﬁned only in chain A, which is likely to be an effect of
crystal packing. The Ramachandran plot reveals good
stereochemistry and negligible steric hindrances between
atoms of the polypeptide backbone, with 99.6% of residue
angles falling within the allowed regions and 96% within
favoured regions (Table 4).
2.5. Structure analysis
Secondary structures were calculated with the PDBSUM
server (Laskowski et al., 2018), including HERA plots of
secondary structure (Hutchinson & Thornton, 1990). The
secondary structure of the A subunit from our 1.89 A˚ reso-
lution holoenzyme structure (PDB entry 6slh), as calculated
with the PDBSUM server, was manually checked against
electron density in Coot (Emsley et al., 2010). This secondary
structure was compared with that deﬁned in the PDB headers
of the 1.5 A˚ resolution human SR structure in complex with
malonate (PDB entry 3l6b; Smith et al., 2010) and the 1.81 A˚
resolution crystal structure of wild-type SR (PDB entry 5x2l;
Takahara et al., 2018). The PDBSUM server deﬁnitions of
secondary structure for PDB entries 3l6b and 5x2l were also
checked (see Supplementary Table S1 for deﬁnitions and
comparisons of secondary-structure elements). This analysis
deﬁned the positions of the ten -strands (1–10), 12
-helices (1–12) and ﬁve 310-helices in our structure
(Supplementary Table S1). We note that although serine
dehydratase belongs to the same overall fold type as SR, it
lacks the N-terminal helix of SR and its C-terminal helix is an
-helix rather than the 310-helix often seen in SR structures
(Supplementary Table S1).
Secondary-structure deﬁnitions were inserted into the PDB
headers before drawing structures with PyMOL (v.1.5.0.4;
Schro¨dinger). The Kleywegt (Ramachandran) plots (Kleywegt
& Jones, 1996) were drawn in Coot (Emsley et al., 2010). ’– 
angles were calculated with the CCP4 program ANGLES
(Winn et al., 2011) and are presented in Supplementary Table
S2.
The small domain is deﬁned as residues 78–155 and the
large domain as residues 1–68 and 156–316. R.m.s. ﬁts were
calculated with LSQKAB (Winn et al., 2011) for all C atoms
or subsets of C atoms between the A subunit of our new
1.89 A˚ resolution human SR structure and the previously
determined structure in complex with malonate (PDB entry
3l6b) and holo structure in a different cell (PDB entry 5x2l)
(see Supplementary Table S3). In the two holo structures the
large and small domains are in roughly the same position,
whereas in the complex with malonate the small domain is in a
different position with respect to the large domain.
3. Results and discussion
3.1. Human SR holoenzyme structure
The crystal structure of the human SR holoenzyme was
determined to a resolution of 1.89 A˚ in space group P21 and
reveals the large domain (residues 1–68 and 156–316) and the
small domain (residues 78–155) (Fig. 1a) connected by a
ﬂexible loop region (residues 66–77) at the N-terminus of the
small domain. The PLP catalytic cofactor is covalently linked
to Lys56 via a Schiff-base linkage between the side chain of
the lysine and the carbonyl C atom of PLP. The C-terminal
-strand (residues 149–151) of the small domain can change its
’– angles (twist) to allow domain movement. Our deﬁnition
of the small domain (residues 78–155) agrees with that taken
from Smith et al. (2010), whereas our deﬁnition of the large
domain (residues 1–68 and 156–316) differs from theirs
research communications
68 Koulouris et al.  Human serine racemase Acta Cryst. (2020). F76, 65–73
Table 4
Structure reﬁnement.
Values in parentheses are for the outer shell.
Resolution range (A˚) 40.874–1.890 (1.939–1.890)
 Cutoff None
No. of reﬂections, working set 93727 (6987)
No. of reﬂections, test set 4925 (351)
Final Rcryst 0.172 (0.294)
Final Rfree 0.216 (0.302)
Cruickshank DPI 0.246†
No. of non-H atoms
Protein 8309
Ion 6
Ligand 124
Water 531
R.m.s. deviations
Bond lengths (A˚) 0.011
Angles () 1.859
Average B factors (A˚2)
Protein 53.0 [46.5 for large domain]‡
Ramachandran plot
Most favoured (%) 96
Allowed (%) 3.6
Outliers (%) 0.4
† Calculated by the Online_DPI server (Kumar et al., 2015). ‡ The small domain had
higher B factors than the large domain.
electronic reprint
(residues 1–68 and 157–340) in that we do not include the
C-terminal 310-helix (residues 319–325) and subsequent dis-
ordered residues. The recently published holoenzyme crystal
structure of wild-type human SR (PDB entry 5x2l; Takahara et
al., 2018), which did not have the two N-terminal mutations
Cys2Asp and CysC6Asp (see Section 2.1), has a very similar
structure at the N-terminus. However, PDB entry 5x2l is
shorter at the C-terminus (the last residue is 317) and does not
have the C-terminal 310-helix (see Supplementary Table S1 for
a description of the secondary-structural elements used in this
paper). Regardless of some local structural differences, the
overall structures of PDB entries 6slh and 5x2l superpose well,
with a C r.m.s.d. of 0.55 A˚.
The C-terminal helix (residues 319–325) of PDB entry 6slh
is located at the dimer interface and appears to have some
degree of ﬂexibility, which may reﬂect a role in dimerization
and stabilization of the protein complex. Indeed, the
C-terminal 310-helices are in close proximity to each other in
chains A/C and B/D, and the interfaces of each pair of helices
are lined with hydrophobic residues (Leu319, Thr320, Ile323
and Val326) that indicate the presence of dimerizing hydro-
phobic interactions. It has been suggested that the activity of
SR may be regulated by interactions of its C-terminal residues
with a PDZ domain from GRIP (Baumgart et al., 2007).
In accordance with the characteristics of fold type II PLP-
dependent enzymes, our SR holoenzyme structure reveals a
small domain with a central -sheet consisting of four parallel
-strands (residues 78–81, 101–108, 124–128 and 149–151)
ﬂanked by two -helices on one side (residues 85–98 and 111–
121) and one -helix (residues 131–146) on the other side. The
large domain has a six-stranded -sheet core surrounded by
-helices, and this domain arrangement is conserved between
the malonate complex (PDB entry 3l6b) and our holoenzyme
structure. A magnesium ion resides in the divalent cation-
binding site, where it is coordinated by three buried waters,
two acidic side chains (Glu210 and Asp216) and the
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Figure 1
Overall comparison of the new holo human SR structure with that of a malonate complex (PDB entry 3l6b). (a) One human SR monomer from the
1.89 A˚ resolution holo structure. Each subunit has a large domain (dark blue) and a small domain (cyan). The C-terminal 310-helix is shown in grey. The
essential cofactor PLP covalently bound to Lys56 is shown in sphere representation. (b) The human SR subunit from the structure with malonate (orange
spheres) is shown with the small domain in pale green and the large domain in dark green. (c) Superposition of the large domains of the structures in (a)
and (b). Note how most, but not all, of the small domain is shifted. (d) Close-up view of the malonate-binding site in a similar orientation to (b).
electronic reprint
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Figure 2
Superposition of the small domains of human SR structures. (a) The small domain (cyan) from the 1.89 A˚ resolution human SR structure contains
secondary-structural elements labelled -3, -4, -4, -5, -5, -6 and -6. Also shown are main-chain hydrogen bonds (dark blue), the C-terminal
310-helix (dark grey) and the 67–77 loop (dark grey). The Ser84 side chain (modelled in two rotamers) is shown in stick representation. (b) PLP attached
to Lys56 drawn withMarvinSketch using the most likely tautomer at pH 7.0 (there are 14 possible tautomers between pH 4 and 10). (c) The human SR
subunit from a structure with malonate (PDB entry 3l6b) is shown with the small domain in yellow and the large domain in light green. The Ser84 side
chain is shown in stick representation pointing at malonate (orange sticks). Main-chain hydrogen bonds are shown in orange. (d) Chemical
representation of the structure in (c). Dotted lines are possible hydrogen bonds (length of <3.3 A˚). (e) Superposition of the small domains of the
structures in (a) and (c). Note how most of the small domain is reasonably well superposed, but Ser84 and the -4 helix are in different positions. ( f )
Ser84 is believed to protonate the substrate serine to convert it to d-serine.
electronic reprint
main-chain carbonyl of Ala214, thus helping to stabilize
protein folding and increase maximal activity (De Miranda et
al., 2002; Bruno et al., 2017). While the domain structure and
most secondary-structural elements are conserved between
SR and SDH, SDH lacks the N-terminal -helix and has a C-
terminal -helix, rather than the C-terminal 310-helix seen in
some human SR structures (Supplementary Table S1).
3.2. The small domain is in an ‘open’ position in the holo
structure
Comparing the structures of holo (Fig. 1a) and malonate-
bound (Fig. 1b) human SR using a superposition based on
residues from the large domains showed a relative large shift
of most of the small domain (Fig. 1c). There is a striking
difference between the accessibility of the active site in the
two structures. In the malonate-bound form (Figs. 1b and 1d)
the small domain is positioned tight against the large domain
to form a ‘closed’ structure in which the catalytic site is in-
accessible to solvent; notably, helices 5 and 6 shift towards
PLP in the large domain by distances of about 5.5 and 8 A˚,
respectively. In the holoenzyme structure, the high degree of
mobility of the small domain and ﬂexible loop region is shown
by the distance between the two domains, creating an ‘open’
position large enough to allow the binding of an amino acid,
small molecule or compound.
When malonate is bound in the active site (Fig. 1d) it forms
hydrogen bonds between its two carboxylic acid groups and
the surrounding residues: the hydroxyl groups of Ser84 and
Ser242, the amino groups of Ser84 and His87 and the side
chain of Arg135 (Fig. 1d). The dual carboxylic acid nature of
malonate allows it to induce a conformational shift linking the
large domain and Ser84, the key catalytic site residue located
in the small domain. In a proposed mechanism of l-serine
isomerization, PLP and l-serine are linked by a protonated
Schiff base, and PLP then deprotonates l-serine to form a
planar intermediate. Ser84 is moved into position via a ligand-
induced shift on the opposite side of the PLP ring plane to
donate a proton from its hydroxyl group and thus invert the
stereochemistry of l-serine to d-serine (Yoshimura, 2008;
Goto et al., 2009).
The commonly accepted reaction mechanism of mammalian
SR is based on data from bacterial enzymes and comparisons
between human, rat and yeast orthologues (Goto et al., 2009;
Smith et al., 2010). The major structural change between
human holo and malonate-bound SR described here further
supports the existence of an analogous mechanism for l-serine
isomerization in the human enzyme. Moreover, the ‘open’
conformation of the human SR holoenzyme suggests that the
active site and key catalytic residues are accessible to small
molecules and compounds, and indicates that SR is structu-
rally enabled for drug-discovery efforts and in silico screening.
3.3. Conformational flexibility with the small domain of
human SR
A superposition of holo (Fig. 2a) and malonate-bound
(Fig. 2c) human SR based on residues from the small domains
(residues 78–155) show that not all residues within the small
domain of human SR ‘move’ with the small domain. Notably,
the 4 helix (residues 85–99) and residues at the C-terminal
end of the domain (residues 153–155) do not move with the
rest of the small domain but seem to remain relatively static
with regard to the large domain (Fig. 1c). Thus, we have
deﬁned a small mobile subdomain (residues 78–81 and 101–
148) which appears to be linked to the rest of SR by four
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Figure 3
Conformational ﬂexibility within the small domain of the human SR
structure. (a) Main-chain atoms from the small domain of human SR,
close to Ser84, are shown with N atoms in blue, O atoms in red, C atoms in
cyan for the holo structure and yellow for the malonate-bound structure
(PDB entry 3l6b), and main-chain hydrogen bonds as dashed blue or
orange lines. The small domains are superposed as in Fig 2(c). The loop
connecting the C-terminus of 3 to the N-terminus of 4 has a different
conformation, and the 4 helix from the small domain is not well
superposed. (For clarity, only the side chains of His82 and Ser84 are
shown. Note how the carbonyl O atoms of His82, which are ringed, are
pointing in different directions.) (b) A Kleywegt plot comparing the small
domain of holo SR (subunit D) with that in a malonate-bound structure
(PDB entry 3l6b). The plot shows arrows between the same residue in the
two structures. Residues that have large differences in ’– are labelled
(blue for holo ’– , orange for malonate ’– ). The ’– angles in this
region are presented in Supplementary Table S2.
electronic reprint
ﬂexible hinge regions (residues 68–77, 82–85, 99–101 and 149–
151), which were deﬁned based on further analysis of the small
domain (Fig. 3). Our data show that the loop that contains
Ser84 undergoes a dramatic change in conformation between
the holo and ligand-bound structures (Fig. 3a), with two
residues, His82 and Gly85, having very different conforma-
tions (Fig. 3b). A comparison of ’– angles (Supplementary
Table S2) demonstrates that not only are there dramatic
changes in the ’– angles of His82 and Gly85, but that there is
a consistent change in the ’– angles of the three residues in
the ﬁnal -strand of the small domain (residues 149–151;
Supplementary Table S2). This -strand (residues 149–151),
acting as a ﬂexible hinge region, is relatively well superposed
whether the superposition is based on the large domain
(Fig. 1c) or the small domain (Fig. 2c). Furthermore, a
signiﬁcant change in the conformation of residues 82–85
(Fig. 3) indicates that this is an additional loop region, which
may function to prevent any catalysis occurring until the
substrate is fully captured in an enclosed active site.
4. Discussion
When large structural movements take place within a single
globular structural domain (for example between the GDP-
and GTP-bound forms of the small GTPase ARF; Goldberg,
1998), subdivision of the structural domain into subdomains
that ‘move’ relative to each other in different states of the
protein may become relevant. We have analysed secondary-
and tertiary-structure elements in our human holoenzyme SR
structure and in a malonate complex of SR (PDB entry 3l6b)
to deﬁne ‘moving’ and ‘relatively static’ subdomains within the
small domain of human serine racemase, and we show that
only part of the small domain moves upon the binding of
malonate. While the crystal structure presented here appears
to have high global structural homology to previous SR
structures (PDB entries 5x2l and 3l6b), our observations
regarding the movement of the small domain subdomain and
the presence of four ﬂexible hinge regions differs from
previous assertions in that the ligand binding induced move-
ment of the entire small domain ﬂanked by two loop regions
(Smith et al., 2010). Structural knowledge of SR subdomain
rearrangement is important for in silico drug design,
pharmacophore modelling and screening, and provides addi-
tional information for determining how conformational
changes of the hinge regions and subdomain alter binding in
the active site.
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